Impact of Travel Time on Health Care Costs and Resource Use by Phase of Care for Older Patients With Cancer Although patients with NSCLC treated with ≥ 10 mg of prednisone at the time of immunotherapy ...
Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non–Small-Cell Lung Cancer D.N.-F. was partially supported by the ...
Beyond Convenience: Does Subcutaneous Pembrolizumab Add Value for Patients and Health Systems? The following represents disclosure information provided by authors of this manuscript. All relationships ...
Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway Are Associated With Clinical Outcomes in Esophageal Cancer Patients Treated With Chemoradiotherapy A significant overall survival (OS) benefit of ...
The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...
Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma Eligible survivors of ...
At a cancer center in Alberta, Canada, consecutive patients with cancer (lung or GI; N = 1,473) were assessed at presentation for weight loss history, lumbar skeletal muscle index, and mean muscle ...
Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720 Most ...
Adjuvant Endocrine Therapy Compared With No Systemic Therapy for Elderly Women With Early Breast Cancer: 21-Year Results of International Breast Cancer Study Group Trial IV Purpose: This retrospective ...
View the current volume of the ASCO Educational Book ...
The MTD for GMTZ in combination with cytarabine and mitoxantrone was 3 mg/m 2 while the MTD in combination with cytarabine and l-asparaginase was 2 mg/m 2. Toxicities observed in both treatment ...
This review highlights the evidence-based data to support current best management practices for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Current ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results